Abstract
Urothelial carcinoma has become the ninth most common malignancy in the world. Since the 1980s, diverse studies and treatment methods came out with their possible effects along with certain limitations. Initially, platinum chemotherapy was considered as first-line treatment of the disease. Although it was proved to be effective initially, the most number of cases reported the reoccurrence of the disease. Furthermore, aberrant ligand- dependent and constitutive ligand-independent fibroblast growth factor receptor (FGFR) signaling has been reported in a large number of solid tumors, including urothelial carcinoma that became the basis for FGFR inhibition for the treatment of the disease. Erdafitinib is a pan-FGFR inhibitor that was recently approved in the USA for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma. The drug is also being investigated as a treatment for other cancers, including cholangiocarcinoma, liver cancer, non-small cell lung cancer, prostate cancer, lymphoma cancer and oesophageal cancer. This article summarizes the various treatments that evolved for bladder cancer till now, a brief description of the biology of FGFR inhibition, clinical pharmacology, and various clinical trials of erdafitinib.
Keywords: Urinary bladder neoplasm, chemotherapy adjuvant, fibroblast growth factor, pharmacokinetics, pharmacodynamics, clinical trials, erdafitinib.
Anti-Cancer Agents in Medicinal Chemistry
Title:Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma
Volume: 21 Issue: 18
Author(s): Parveen Bansal, Deepak K. Dwivedi, Deepa Hatwal, Priyanka Sharma, Vikas Gupta, Suresh Goyal and Mukesh Maithani*
Affiliation:
- Multidisciplinary Research Unit, Veer Chandra Singh Garhwali Government Institute of Medical Science and Research, Srinagar, Pauri Garhwal,India
Keywords: Urinary bladder neoplasm, chemotherapy adjuvant, fibroblast growth factor, pharmacokinetics, pharmacodynamics, clinical trials, erdafitinib.
Abstract: Urothelial carcinoma has become the ninth most common malignancy in the world. Since the 1980s, diverse studies and treatment methods came out with their possible effects along with certain limitations. Initially, platinum chemotherapy was considered as first-line treatment of the disease. Although it was proved to be effective initially, the most number of cases reported the reoccurrence of the disease. Furthermore, aberrant ligand- dependent and constitutive ligand-independent fibroblast growth factor receptor (FGFR) signaling has been reported in a large number of solid tumors, including urothelial carcinoma that became the basis for FGFR inhibition for the treatment of the disease. Erdafitinib is a pan-FGFR inhibitor that was recently approved in the USA for the treatment of locally advanced or metastatic FGFR3 or FGFR2 urothelial carcinoma. The drug is also being investigated as a treatment for other cancers, including cholangiocarcinoma, liver cancer, non-small cell lung cancer, prostate cancer, lymphoma cancer and oesophageal cancer. This article summarizes the various treatments that evolved for bladder cancer till now, a brief description of the biology of FGFR inhibition, clinical pharmacology, and various clinical trials of erdafitinib.
Export Options
About this article
Cite this article as:
Bansal Parveen, Dwivedi K. Deepak , Hatwal Deepa , Sharma Priyanka , Gupta Vikas , Goyal Suresh and Maithani Mukesh *, Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma, Anti-Cancer Agents in Medicinal Chemistry 2021; 21 (18) . https://dx.doi.org/10.2174/1871520621666210121093852
DOI https://dx.doi.org/10.2174/1871520621666210121093852 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
Call for Papers in Thematic Issues
Discovery of Lead compounds targeting transcriptional regulation
Transcriptional regulation plays key physiological functions in body growth and development. Transcriptional dysregulation is one of the important biomarkers of tumor genesis and progression, which is involved in regulating tumor cell processes such as cell proliferation, differentiation, and apoptosis. Additionally, it plays a pivotal role in angiogenesis and promotes tumor ...read more
Induction of cell death in cancer cells by modulating telomerase activity using small molecule drugs
Telomeres are distinctive but short stretches present at the corners of chromosomes that aid in stabilizing chromosomal makeup. The resynthesis of telomeres is supported by the activity of reverse transcriptase ribonucleoprotein complex telomerase. There is no telomerase activity in human somatic cells, but the stem cells and germ cells undergo ...read more
Innovative targets in medicinal chemistry
Medicinal chemistry continuously evolves in response to emerging healthcare needs and advancements in scientific understanding. This special issue explores the current landscape of innovative targets in medicinal chemistry, highlighting the quest for novel therapeutic avenues. From traditional drug targets such as enzymes and receptors to emerging targets like protein-protein interactions ...read more
Rechallenge Therapy in different types of cancer
Cancer is responsible for approximately 8 million deaths annually worldwide. GLOBOCAN 2020 reported 19.3 million new cases of cancer, which is projected to increase to 28.4 million by 2040. In the future, female breast cancer will be the most common cancer (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors
Current Medicinal Chemistry - Anti-Cancer Agents Probiotics: An Emerging Therapy
Current Pharmaceutical Design Mast Cells in Allergic and Inflammatory Diseases
Current Pharmaceutical Design The Relevance of IgE in the Pathogenesis of Allergy: The Effect of an Anti-IgE Drug in Asthma and Other Diseases
Recent Patents on Inflammation & Allergy Drug Discovery Treating Benign Prostatic Hyperplasia with Botulinum Neurotoxin
Current Medicinal Chemistry Computational Methods and Algorithms for Mass-Spectrometry Based Differential Proteomics
Current Proteomics Neurophysiological Mechanisms Related to Pain Management in Bone Tumors
Current Neuropharmacology Radiolabeled Peptides for Alzheimer’s Diagnostic Imaging: Mini Review
Current Radiopharmaceuticals The Engaged Role of Tumor Microenvironment in Cancer Metabolism: Focusing on Cancer-Associated Fibroblast and Exosome Mediators
Anti-Cancer Agents in Medicinal Chemistry Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases
Current Cancer Drug Targets Targeting Mitochondria in Fighting Cancer
Current Pharmaceutical Design Molecular and Genetic Bases of Pancreatic Cancer
Current Drug Targets Synthetic Lethality-Based Therapeutics: Perspectives for Applications in Colorectal Cancer
Current Cancer Drug Targets Estrogen Receptor Signaling: Impact on Cell Functions
Current Signal Transduction Therapy The Role of the RhoA/rho-kinase Pathway in Pulmonary Hypertension
Current Drug Discovery Technologies Chemical Strategies towards the Development of Effective Anticancer Peptides
Current Medicinal Chemistry New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Current Cancer Drug Targets Meet Our Editorial Board Member
Anti-Cancer Agents in Medicinal Chemistry MicroRNAs Regulate the Epithelial to Mesenchymal Transition (EMT) in Cancer Progression
MicroRNA Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design